{"id":68792,"date":"2026-06-24T00:35:13","date_gmt":"2026-06-23T16:35:13","guid":{"rendered":"https:\/\/flcube.com\/?p=68792"},"modified":"2026-06-24T00:35:14","modified_gmt":"2026-06-23T16:35:14","slug":"china-medical-systems-silvemimab-becomes-worlds-first-dual-epitope-fully-human-rabies-antibody-approved-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68792","title":{"rendered":"China Medical System&#8217;s Silvemimab Becomes World&#8217;s First Dual-Epitope Fully Human Rabies Antibody Approved in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China Medical System Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>Marketing Authorization Application (MAA)<\/strong> for its <strong>Class 1 therapeutic biologic<\/strong>, <strong>silvemimab injection<\/strong> (trade name: <strong>Jinsuxi<\/strong>; developmental code: <strong>GR1801<\/strong>), for <strong>post-exposure prophylaxis (passive immunization) against rabies virus in adults<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-details\" class=\"wp-block-heading\">Regulatory Milestone Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>China Medical System Holdings Limited (HKG: 0867)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Silvemimab injection (Jinsuxi, GR1801)<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June 23, 2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Post-exposure prophylaxis (passive immunization) against rabies virus in adults<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Class 1 therapeutic biologic<\/td><\/tr><tr><td><strong>Global Significance<\/strong><\/td><td><strong>World&#8217;s first fully human specific antibody targeting dual epitopes of rabies virus<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-profile\" class=\"wp-block-heading\">Product Innovation Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Recombinant <strong>fully human anti-rabies virus bispecific antibody<\/strong><\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Simultaneously targets <strong>epitopes I and III<\/strong> of rabies virus (RABV) envelope glycoprotein (G protein)<\/li>\n\n\n\n<li><strong>Therapeutic Action:<\/strong> Blocks virus-receptor binding and neutralizes rabies virus before active vaccine immunity develops<\/li>\n\n\n\n<li><strong>WHO Alignment:<\/strong> Implements the recommended <strong>&#8220;cocktail&#8221; treatment approach<\/strong> through single-molecule dual-epitope targeting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-advantages\" class=\"wp-block-heading\">Competitive Advantages<\/h2>\n\n\n\n<h3 id=\"h-safety-amp-manufacturing-benefits\" class=\"wp-block-heading\">Safety &amp; Manufacturing Benefits:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>No blood-borne infection risk<\/strong> (recombinant production vs. plasma-derived alternatives)<\/li>\n\n\n\n<li><strong>Large-scale, standardized, and stable manufacturing<\/strong> capability<\/li>\n\n\n\n<li><strong>Immediate protection<\/strong> bridging the gap until active vaccine immunity takes effect<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-patient-centric-features\" class=\"wp-block-heading\">Patient-Centric Features:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lowest dosage volume<\/strong> among current passive rabies immunization agents<\/li>\n\n\n\n<li><strong>Reduced injection pain<\/strong> due to smaller volume requirements<\/li>\n\n\n\n<li><strong>Improved patient compliance<\/strong> through enhanced tolerability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressing Critical Need:<\/strong> Rabies remains a significant public health concern in China with thousands of annual exposures requiring post-exposure prophylaxis<\/li>\n\n\n\n<li><strong>Market Disruption Potential:<\/strong> Positions to replace plasma-derived rabies immunoglobulin (RIG) products currently dominating the market<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Chinese rabies passive immunization market estimated at \u00a5800 million\u2013\u00a51.2 billion annually with premium pricing potential<\/li>\n\n\n\n<li><strong>Global Expansion Pathway:<\/strong> First-in-class status and WHO alignment support international regulatory submissions beyond China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-context\" class=\"wp-block-heading\">Development Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a major breakthrough in rabies prevention therapy, transitioning from traditional plasma-derived products to modern recombinant antibody technology. The dual-epitope approach provides superior neutralization breadth compared to single-epitope antibodies, while the fully human design eliminates immunogenicity concerns associated with animal-derived or chimeric antibodies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The emphasis on low dosage volume addresses a key limitation of current RIG products, which require large injection volumes that cause significant patient discomfort and compliance challenges, particularly in pediatric populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ materially due to risks including market adoption rates, competitive dynamics, pricing negotiations, and manufacturing scale-up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200749_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026062200749_c.\"><\/object><a id=\"wp-block-file--media-daa72ec1-4515-40f0-abae-a6563ad18b8e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200749_c.pdf\">2026062200749_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200749_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-daa72ec1-4515-40f0-abae-a6563ad18b8e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[325,844,15],"class_list":["post-68792","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-china-medical-system","tag-hkg-0867","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System&#039;s Silvemimab Becomes World&#039;s First Dual-Epitope Fully Human Rabies Antibody Approved in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System&#039;s Silvemimab Becomes World&#039;s First Dual-Epitope Fully Human Rabies Antibody Approved in China\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68792\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T16:35:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T16:35:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System&#8217;s Silvemimab Becomes World&#8217;s First Dual-Epitope Fully Human Rabies Antibody Approved in China\",\"datePublished\":\"2026-06-23T16:35:13+00:00\",\"dateModified\":\"2026-06-23T16:35:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"HKG: 0867\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68792#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68792\",\"name\":\"China Medical System's Silvemimab Becomes World's First Dual-Epitope Fully Human Rabies Antibody Approved in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-23T16:35:13+00:00\",\"dateModified\":\"2026-06-23T16:35:14+00:00\",\"description\":\"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68792\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System&#8217;s Silvemimab Becomes World&#8217;s First Dual-Epitope Fully Human Rabies Antibody Approved in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System's Silvemimab Becomes World's First Dual-Epitope Fully Human Rabies Antibody Approved in China - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68792","og_locale":"en_US","og_type":"article","og_title":"China Medical System's Silvemimab Becomes World's First Dual-Epitope Fully Human Rabies Antibody Approved in China","og_description":"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.","og_url":"https:\/\/flcube.com\/?p=68792","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-23T16:35:13+00:00","article_modified_time":"2026-06-23T16:35:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68792#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68792"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System&#8217;s Silvemimab Becomes World&#8217;s First Dual-Epitope Fully Human Rabies Antibody Approved in China","datePublished":"2026-06-23T16:35:13+00:00","dateModified":"2026-06-23T16:35:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68792"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","HKG: 0867","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68792#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68792","url":"https:\/\/flcube.com\/?p=68792","name":"China Medical System's Silvemimab Becomes World's First Dual-Epitope Fully Human Rabies Antibody Approved in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-23T16:35:13+00:00","dateModified":"2026-06-23T16:35:14+00:00","description":"China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for its Class 1 therapeutic biologic, silvemimab injection (trade name: Jinsuxi; developmental code: GR1801), for post-exposure prophylaxis (passive immunization) against rabies virus in adults.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68792"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System&#8217;s Silvemimab Becomes World&#8217;s First Dual-Epitope Fully Human Rabies Antibody Approved in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68792"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68792\/revisions"}],"predecessor-version":[{"id":68794,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68792\/revisions\/68794"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}